Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

• Detail clinical infrastructure changes that may be needed to address the growing population of patients with AD and new treatment options

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.¹ Though there are currently only symptomatic therapies available, amyloid- and tau-targeted therapies are on the horizon. With the approval of new therapies for AD, particularly monoclonal antibodies administered via infusion, clinic infrastructure will need to quickly adapt to select patients most appropriate for newly available therapy, demonstrate patient eligibility, provide on-site resources and equipment for patients and clinicians, and work with managed care to ensure coverage for these therapies.^2-4 Changes on this scale will be challenging for everyone, ranging from small, private practices to large clinics at academic centers, and it is in clinicians’ and patients’ best interest to begin preparation for the coming changes now. Dr. Sabbagh provides his expert insight into how clinicians can prepare for significant changes in clinic infrastructure, the types of protocols that will be necessary, and strategies to work with managed care to facilitate patient access to newly approved therapies.

References

1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
2. Wimo A. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1)1:1-4.
3. Fleming WK, et al. JAMA Health Forum. 2020;1(9):e201148-e201148.
4. Wong W. Am J Manag Care. 2020;26(suppl 8):S177-S183.

Faculty

Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Marwan N. Sabbagh, MD, FAAN:
Consultant/Independent Contractor: Acadia Pharmaceuticals Inc., Alzheon, Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations.
Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC.
Stock Shareholder: Athira Pharma, Brain Health Inc., NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.0 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 100% on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

• Detail clinical infrastructure changes that may be needed to address the growing population of patients with AD and new treatment options

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.¹ Though there are currently only symptomatic therapies available, amyloid- and tau-targeted therapies are on the horizon. With the approval of new therapies for AD, particularly monoclonal antibodies administered via infusion, clinic infrastructure will need to quickly adapt to select patients most appropriate for newly available therapy, demonstrate patient eligibility, provide on-site resources and equipment for patients and clinicians, and work with managed care to ensure coverage for these therapies.^2-4 Changes on this scale will be challenging for everyone, ranging from small, private practices to large clinics at academic centers, and it is in clinicians’ and patients’ best interest to begin preparation for the coming changes now. Dr. Sabbagh provides his expert insight into how clinicians can prepare for significant changes in clinic infrastructure, the types of protocols that will be necessary, and strategies to work with managed care to facilitate patient access to newly approved therapies.

References

1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
2. Wimo A. Expert Rev Pharmacoecon Outcomes Res. 2021;21(1)1:1-4.
3. Fleming WK, et al. JAMA Health Forum. 2020;1(9):e201148-e201148.
4. Wong W. Am J Manag Care. 2020;26(suppl 8):S177-S183.

Faculty

Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Marwan N. Sabbagh, MD, FAAN:
Consultant/Independent Contractor: Acadia Pharmaceuticals Inc., Alzheon, Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations.
Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC.
Stock Shareholder: Athira Pharma, Brain Health Inc., NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.0 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 100% on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

• Assess patients with mild cognitive impairment and AD using cognitive scales, biomarker imaging, clinical examination, and patient/caregiver interviews
• Describe challenges, results, and future directions with emerging therapies for AD

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.¹ Early diagnosis of AD is shaped by patient and caregiver interviews, cognitive testing, and standard imaging. Once diagnosed, patients and their caregivers face numerous challenges, all of which require longitudinal treatment, ongoing monitoring, and an intensive commitment to patient/caregiver education and engagement. Symptomatic therapies are available for patients with AD. The range of neurotransmitter-focused medications, however, is limited.¹ There is a plethora of evidence suggesting active management can improve quality of life if performed correctly. This requires collaborative care, which should include patients and caregivers, education, comorbidity management, social interaction, and appropriate use of available treatments.1 Amyloid- and tau-targeted therapies are in clinical trials, and, if approved, these therapies would change the landscape of AD management.^2,3 It is critical for clinicians to be well educated about current management strategies, collaborative care, patient education, and emerging therapies and patient selection. This self-assessment activity presents real-life case scenarios for clinicians to gauge and learn about optimal practice strategies for diagnosis and management of AD, as well as how emerging therapies may eventually be employed.

References

1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
2. Budd Haeberlein S, et al. Clinical Trials on Alzheimer’s Disease; December 4-7, 2019; San Diego, CA.
3. Congdon EE, Sigurdsson EM. Nat Rev Neurol. 2018;14(7):399-415.

Faculty

Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Marwan N. Sabbagh, MD, FAAN:
Consultant/Independent Contractor: Acadia Pharmaceuticals Inc., Alzheon, Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations.
Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC.
Stock Shareholder: Athira Pharma, Brain Health Inc., NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.1 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 100% on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Activity Details

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

The educational design of this activity addresses the needs of physicians, nurse practitioners, and other allied health care professionals who treat patients with Alzheimer's disease (AD).

Educational Objectives

After completing this activity, the participant should be better able to:

• Assess patients with mild cognitive impairment and AD using cognitive scales, biomarker imaging, clinical examination, and patient/caregiver interviews
• Describe challenges, results, and future directions with emerging therapies for AD

Statement of Educational Need

AD is a common neurodegenerative condition that results in a range of profoundly disabling cognitive, affective, and behavioral symptoms. It affects approximately 5.8 million Americans.¹ Early diagnosis of AD is shaped by patient and caregiver interviews, cognitive testing, and standard imaging. Once diagnosed, patients and their caregivers face numerous challenges, all of which require longitudinal treatment, ongoing monitoring, and an intensive commitment to patient/caregiver education and engagement. Symptomatic therapies are available for patients with AD. The range of neurotransmitter-focused medications, however, is limited.¹ There is a plethora of evidence suggesting active management can improve quality of life if performed correctly. This requires collaborative care, which should include patients and caregivers, education, comorbidity management, social interaction, and appropriate use of available treatments.1 Amyloid- and tau-targeted therapies are in clinical trials, and, if approved, these therapies would change the landscape of AD management.^2,3 It is critical for clinicians to be well educated about current management strategies, collaborative care, patient education, and emerging therapies and patient selection. This self-assessment activity presents real-life case scenarios for clinicians to gauge and learn about optimal practice strategies for diagnosis and management of AD, as well as how emerging therapies may eventually be employed.

References

1. Alzheimer’s Association. 2021 Alzheimer’s Disease Facts and Figures. https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf. Accessed April 6, 2021.
2. Budd Haeberlein S, et al. Clinical Trials on Alzheimer’s Disease; December 4-7, 2019; San Diego, CA.
3. Congdon EE, Sigurdsson EM. Nat Rev Neurol. 2018;14(7):399-415.

Faculty

Marwan N. Sabbagh, MD, FAAN
Director, Cleveland Clinic Lou Ruvo Center for Brain Health
Camille and Larry Ruvo Endowed Chair for Brain Health
Professor of Neurology, Cleveland Clinic Lerner College of Medicine
Clinical Professor, Department of Neurology
University of Nevada, Las Vegas
Las Vegas, Nevada

Conflict of Interest Policy/Disclosure Statement

Global Education Group adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education (CE), set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Marwan N. Sabbagh, MD, FAAN:
Consultant/Independent Contractor: Acadia Pharmaceuticals Inc., Alzheon, Inc., Biogen Inc., Cortexyme, Inc., Danone S.A., Neurotrope Biosciences, Regeneron Pharmaceuticals, Inc., Roche-Genentech, Inc., State 2 Innovations.
Speakers Bureau: Health and Wellness Partners, LLC, Knapp Healthcare Communications, LLC.
Stock Shareholder: Athira Pharma, Brain Health Inc., NeuroReserve Inc., NeuroTau, Inc., Optimal Cognitive Health Company, LLC, uMETHOD Health, Inc., Versanum Inc.

The planners and managers have the following relevant financial relationships with ineligible companies:

Kristin Delisi, NP - Nothing to disclose
Lindsay Borvansky - Nothing to disclose
Andrea Funk - Nothing to disclose
Liddy Knight - Nothing to disclose
Ashley Cann - Nothing to disclose
Gena Dolson, MS - Nothing to disclose
Stacey JP Ullman, MHS - Nothing to disclose

Accreditation Statement

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.25 contact hour (which includes 0.1 hour of pharmacology).

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the pre-test, view the educational content, score 100% on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information

Global Contact Information
For information about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information
For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Activity Details

Accredited By

Target Audience

The intended audience for this activity is neurologists, neurology nursing professionals, pharmacists, physician assistants, and other health care professionals involved in the management of patients with relapsing forms of multiple sclerosis (MS).

Learning Objectives

Upon successful completion of this activity, participants will be able to:

• Identify patients with relapsing forms of multiple sclerosis (MS) who may benefit from existing therapies.
• Examine the comparative mechanisms of action, methods of administration, pharmacological activity, efficacy, and tolerability of current and emerging treatment options for patients with relapsing forms of MS.
• Evaluate the latest clinical evidence regarding new disease-modifying therapies for the management of patients with relapsing forms of MS.

Activity Description

Although rapid advances in the management of patients with multiple sclerosis (MS) are poised to improve patient outcomes, clinical decision-making has become more complex. There are numerous approved and emerging disease-modifying therapies (DMTs) for patients with relapsing forms of MS. Although most patients with MS present with the relapsing form, a staggering 80% go on to develop secondary progressive MS, the course associated with progressive worsening of neurologic function. The expanded pool of DMTs has changed the clinical approach to therapy. Whereas the ability of a therapy to reduce the relapse rate or disability progression has historically driven DMT selection, the emergence of new therapeutic options combined with the longevity and variable disease course of MS necessitates consideration of additional factors, such as safety, convenience, and management of comorbidities. In this continuing educational activity, expert clinicians discuss the latest updates in therapies for MS.

Agenda

Introduction
Patricia K. Coyle, MD, FAAN, FANA

Identifying Relapsing Forms of Multiple Sclerosis: Differentiation of Phenotypes
Patricia Melville, MSN, NP-C, MSCN

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Treating Relapsing Forms of Multiple Sclerosis: Comparing Current and Emerging Agents
Clyde E. Markowitz, MD

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Applying the Latest Evidence: Clinical Implications
Patricia K. Coyle, MD, FAAN, FANA

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Conclusion
Patricia K. Coyle, MD, FAAN, FANA

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director, Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Sanofi Genzyme, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, Sanofi Genzyme, Teva

Patricia Melville, MSN, NP-C, MSCN
Clinical Instructor
Stony Brook MS Comprehensive Care Center
State University of New York
Stony Brook, NY

Disclosures:
Consulting Fee: Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Genentech, Sanofi Genzyme
Speakers Bureau: Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Sanofi Genzyme
Contracted Research: Biogen, Corrona, Genentech, Johnson & Johnson, MedDay, Novartis

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education, American Nurses Credentialing Center’s Commission on Accreditation, Accreditation Council for Pharmacy Education, and American Academy of Physician Assistants’ Standards for Integrity and Independence in Accredited Continuing Education, all accredited providers are required to identify, mitigate and disclose to the activity audience the financial relationships with ineligible companies of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 24 months with an ineligible company and manage those relationships such that there is no presence of commercial bias in the education. Relationship information is accurate at the time of content development.

Planners/Reviewers
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have declared that they have no relevant financial relationships to disclose.

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI,CHCP, served as planner and reviewer and has declared that he has no relevant financial relationships to disclose.

The Consortium of Multiple Sclerosis Centers Staff
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at The Consortium of Multiple Sclerosis Centers and Vindico Medical Education, Offices of Medical Affairs and Compliance.

Accreditation Statement

The Consortium of Multiple Sclerosis Centers is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Consortium of Multiple Sclerosis Centers is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria.

Designation of Credit

The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Consortium of Multiple Sclerosis Centers will provide a maximum of 1.0 contact hour(s) for nurses.

This program is acceptable for 1.0 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-9999-21-002-H01-P, effective 3/12/21. This is a knowledge-based activity, and there is no fee to attend.

This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until March 11, 2022. PAs should only claim credit commensurate with the extent of their participation.

This enduring material is approved for 1 year from the date of original release, March 12, 2021 to March 11, 2022.

Instructions for Receiving Credit

To participate in this CE activity, you must read the learning objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, The Consortium of Multiple Sclerosis Centers will issue an AMA PRA Category 1 Credit(s)™ Certificate, Learner Paced Contact Hour(s) Certificate, or AAPA Category 1 CME Certificate or Vindico Medical Education will issue a CPE statement of credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly.

Statement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education. Neither The Consortium of Multiple Sclerosis Centers, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

CME/CNE/AAPA Questions?
Contact us at education@mscare.org

CPE Questions?
Contact us at CME@VindicoCME.com

Activity Details

Accredited By

Target Audience

The intended audience for this activity is neurologists, neurology nursing professionals, pharmacists, physician assistants, and other health care professionals involved in the management of patients with relapsing forms of multiple sclerosis (MS).

Learning Objectives

Upon successful completion of this activity, participants will be able to:

• Identify patients with relapsing forms of multiple sclerosis (MS) who may benefit from existing therapies.
• Examine the comparative mechanisms of action, methods of administration, pharmacological activity, efficacy, and tolerability of current and emerging treatment options for patients with relapsing forms of MS.
• Evaluate the latest clinical evidence regarding new disease-modifying therapies for the management of patients with relapsing forms of MS.

Activity Description

Although rapid advances in the management of patients with multiple sclerosis (MS) are poised to improve patient outcomes, clinical decision-making has become more complex. There are numerous approved and emerging disease-modifying therapies (DMTs) for patients with relapsing forms of MS. Although most patients with MS present with the relapsing form, a staggering 80% go on to develop secondary progressive MS, the course associated with progressive worsening of neurologic function. The expanded pool of DMTs has changed the clinical approach to therapy. Whereas the ability of a therapy to reduce the relapse rate or disability progression has historically driven DMT selection, the emergence of new therapeutic options combined with the longevity and variable disease course of MS necessitates consideration of additional factors, such as safety, convenience, and management of comorbidities. In this continuing educational activity, expert clinicians discuss the latest updates in therapies for MS.

Agenda

Introduction
Patricia K. Coyle, MD, FAAN, FANA

Identifying Relapsing Forms of Multiple Sclerosis: Differentiation of Phenotypes
Patricia Melville, MSN, NP-C, MSCN

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Treating Relapsing Forms of Multiple Sclerosis: Comparing Current and Emerging Agents
Clyde E. Markowitz, MD

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Applying the Latest Evidence: Clinical Implications
Patricia K. Coyle, MD, FAAN, FANA

Panel Discussion
Moderated by Patricia K. Coyle, MD, FAAN, FANA

Conclusion
Patricia K. Coyle, MD, FAAN, FANA

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director, Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Sanofi Genzyme, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, Sanofi Genzyme, Teva

Patricia Melville, MSN, NP-C, MSCN
Clinical Instructor
Stony Brook MS Comprehensive Care Center
State University of New York
Stony Brook, NY

Disclosures:
Consulting Fee: Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Genentech, Sanofi Genzyme
Speakers Bureau: Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Novartis, Sanofi Genzyme
Contracted Research: Biogen, Corrona, Genentech, Johnson & Johnson, MedDay, Novartis

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education, American Nurses Credentialing Center’s Commission on Accreditation, Accreditation Council for Pharmacy Education, and American Academy of Physician Assistants’ Standards for Integrity and Independence in Accredited Continuing Education, all accredited providers are required to identify, mitigate and disclose to the activity audience the financial relationships with ineligible companies of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 24 months with an ineligible company and manage those relationships such that there is no presence of commercial bias in the education. Relationship information is accurate at the time of content development.

Planners/Reviewers
June Halper, MSN, APN-C, MSCN, FAAN, and Laurie Scudder, DNP, NP, served as planners and reviewers and have declared that they have no relevant financial relationships to disclose.

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI,CHCP, served as planner and reviewer and has declared that he has no relevant financial relationships to disclose.

The Consortium of Multiple Sclerosis Centers Staff
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed Disclosures are on file at The Consortium of Multiple Sclerosis Centers and Vindico Medical Education, Offices of Medical Affairs and Compliance.

Accreditation Statement

The Consortium of Multiple Sclerosis Centers is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Consortium of Multiple Sclerosis Centers is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria.

Designation of Credit

The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Consortium of Multiple Sclerosis Centers will provide a maximum of 1.0 contact hour(s) for nurses.

This program is acceptable for 1.0 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-9999-21-002-H01-P, effective 3/12/21. This is a knowledge-based activity, and there is no fee to attend.

This activity is designated for 1.0 AAPA Category 1 CME credit(s). Approval is valid until March 11, 2022. PAs should only claim credit commensurate with the extent of their participation.

This enduring material is approved for 1 year from the date of original release, March 12, 2021 to March 11, 2022.

Instructions for Receiving Credit

To participate in this CE activity, you must read the learning objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, The Consortium of Multiple Sclerosis Centers will issue an AMA PRA Category 1 Credit(s)™ Certificate, Learner Paced Contact Hour(s) Certificate, or AAPA Category 1 CME Certificate or Vindico Medical Education will issue a CPE statement of credit. Pharmacist learners who submit their NABP and DOB will be reported to the CPE Monitor by Vindico Medical Education directly.

Statement of Commercial Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of The Consortium of Multiple Sclerosis Centers and Vindico Medical Education. Neither The Consortium of Multiple Sclerosis Centers, Vindico Medical Education, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Contact Information for Questions About the Activity

CME/CNE/AAPA Questions?
Contact us at education@mscare.org

CPE Questions?
Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objective

Upon successful completion of the activity, participants should be better able to:

• Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Clyde Markowitz will discuss latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with multiple sclerosis during postpartum/lactation.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech/Roche, Janssen, Novartis, Sanofi/Genzyme, Teva

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Accredited By

This continuing education activity is provided by

Target Audience

The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the management of patients with multiple sclerosis (MS).

Learning Objective

Upon successful completion of the activity, participants should be better able to:

• Apply the latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with MS during prepregnancy, pregnancy, and postpartum/lactation.

Activity Description

In this Curbside Consult, Drs. Patricia Coyle and Clyde Markowitz will discuss latest clinical evidence and guidelines to determine the most appropriate disease-modifying therapies in women with multiple sclerosis during postpartum/lactation.

Activity Chair

Patricia K. Coyle, MD, FAAN, FANA
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

Disclosures:
Consulting Fee: Accordant, Biogen, Bristol Myers Squibb, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
Speakers Bureau: Biogen, Janssen
Contracted Research: Actelion, Alkermes, Corrona, Genentech/Roche, MedDay, NINDS, Novartis

Faculty

Clyde E. Markowitz, MD
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA

Disclosures:
Consulting Fee: Actelion, Alexion, Bayer, Biogen, Celgene/Bristol Myers Squibb, EMD Serono, Genentech/Roche, Janssen, Novartis, Sanofi/Genzyme, Teva

Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Barbara A. Niedz, PhD, RN, CPHQ
Disclosures:
Consulting Fee: Beckton Dickinson
Contracted Research: Beckton Dickinson

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Disclosures:
Consulting Fee: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Roche, Viela Bio
Speakers Bureau: Alexion, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Viela Bio

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education will provide a maximum of 0.25 contact hour(s) for nurses. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Contact Hour(s) Certificate.

Statement of Commercial Support

This activity is supported by educational grants from Biogen, EMD Serono, and Sanofi Genzyme.

There is no non-commercial support for this activity.

Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com